Sight Sciences
Sight Sciences' revenue fell 3.1% to $77 million in fiscal 2025. Its operating margin was −48.0%, up from −63.3% a year earlier. Free cash flow was −$30 million. The diluted share count rose 4.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Sight Sciences does
Sight Sciences is a medical device company that makes tools for eye doctors to treat two eye conditions: glaucoma and dry eye disease. It sells to eyecare professionals, meaning ophthalmologists and optometrists, who use its devices in procedures. The products are used a limited number of times, so revenue depends on how often doctors use them.
It reports an Interventional Glaucoma line and an Interventional Dry Eye line. The glaucoma line has two products for minimally invasive glaucoma surgery: the OMNI Surgical System, a single-use handheld device that treats the eye's drainage pathway to lower eye pressure, and the SION Surgical Instrument, a bladeless tool that removes tissue in the drainage pathway. The dry eye line is TearCare, which uses a reusable controller and wearable eyelid pieces to heat and clear blocked oil glands. It sells OMNI and SION in the U.S. mainly through its own sales team.
The company says it competes with companies that have more financial and human resources, longer histories and established doctor relationships. It also says insurance coverage and payment for the procedures matter to its sales. As of December 31, 2025, it had 186 full-time employees.
Its biggest risks, as it describes them
- It has a history of losses and depends heavily on sales of its few products.
- Insurers may not cover or pay enough for procedures that use its glaucoma and dry eye products.
- Eye doctors may not adopt its products, and they need training and patient selection to use them well.
- It faces competitors with longer histories and more resources, and new treatments could emerge.
- It relies on third-party manufacturers, some single-source suppliers, many of them outside the U.S.
Income statement
Sight Sciences lost money in fiscal 2025: a net loss of $38 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 261 | 185 | 138 | 120 | 92 |
| Debt incl. finance leases | 35 | 35 | 35 | 40 | 42 |
| Net debt (negative means net cash) | −226 | −150 | −103 | −80 | −50 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.1x | 0.2x | 0.3x | 0.5x | 0.7x |
| Interest coverage | −11.8x | −18.8x | −10.6x | −10.8x | −7.2x |
| Current ratio | 20.5x | 11.8x | 13.3x | 9.0x | 10.2x |
| Quick ratio | 20.3x | 11.4x | 12.7x | 8.6x | 9.5x |
Cash flow
Projections
Project Sight Sciences' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $184,799 of Sight Sciences shares on the open market, and 6 insiders sold $2.3 million, $1.7 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | Brenton TaylorEVP, Operations & R&D | Sold plan | 20,685 | $10.64 | $220,006 | Form 4 |
| Jul 6, 2026 | Jeremy B. HaydenChief Legal Officer | Sold plan | 12,733 | $5.51 | $70,159 | Form 4 |
| Jul 6, 2026 | David BadawiChief Technology Officer, Director | Sold plan | 7,418 | $5.51 | $40,873 | Form 4 |
| Jul 2, 2026 | Alison BauerleinChief Operating Officer | Sold plan | 24,184 | $5.36 | $129,626 | Form 4 |
| Jul 2, 2026 | James RodbergChief Financial Officer | Sold plan | 6,902 | $5.36 | $36,995 | Form 4 |
| Jul 1, 2026 | Paul BadawiPresident and CEO, Director, 10% owner | Sold plan | 28,684 | $5.42 | $155,467 | Form 4 |
| Jul 1, 2026 | Brenton TaylorEVP, Operations & R&D | Sold plan | 2,829 | $5.42 | $15,333 | Form 4 |
| Jun 10, 2026 | Staffan EncrantzDirector, 10% owner | Bought | 14,100 | $4.88 | $68,808 | Form 4 |
| May 18, 2026 | Alison BauerleinChief Operating Officer | Sold plan | 12,728 | $5.12 | $65,167 | Form 4 |
| Apr 6, 2026 | Jeremy B. HaydenChief Legal Officer | Sold plan | 13,761 | $3.55 | $48,852 | Form 4 |
| Apr 6, 2026 | James RodbergChief Financial Officer | Sold plan | 7,231 | $3.55 | $25,670 | Form 4 |
| Apr 2, 2026 | Alison BauerleinChief Operating Officer | Sold plan | 25,874 | $3.48 | $90,042 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 3 of 9 | 5 of 9 |
| Rule of 40 | −45.5% | −29.9% | −41.8% |
| Altman Z'' | 0.57 | −2.91 | −5.95 |
| Accruals ratio | −4.4% | −18.8% | −6.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 5 of 9 | 3 of 9 | 5 of 9 |
Compare
Put Sight Sciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Sight Sciences | FY25 | −3.1% | −48.0% | −38.7% | — | — | 5 | |
| Pro Dex | FY26 | 16.4% | 16.8% | 8.7% | 19.6% | 0.6x | 7 | Compare |
| TELA Bio | FY25 | 15.8% | −42.0% | −35.7% | −190.2% | — | 4 | Compare |
| Electromed | FY26 | 15.3% | 18.8% | 11.4% | — | — | — | Compare |
| AVITA Medical | FY25 | 11.4% | −59.4% | −45.0% | −354.1% | — | 2 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 28 | 49 | 71 | 81 | 80 | 77 |
| Revenue growth | — | 77.1% | 45.7% | 13.6% | −1.5% | −3.1% |
| Gross profit | 18 | 40 | 59 | 69 | 68 | 67 |
| Research and development | 9 | 16 | 23 | 18 | 18 | 15 |
| Operating income | −32 | −52 | −84 | −57 | −50 | −37 |
| Net income | −35 | −63 | −86 | −56 | −52 | −38 |
| Diluted EPS (US$) | −3.71 | −2.36 | −1.80 | −1.14 | −1.03 | −0.74 |
| Diluted shares (millions) | 9 | 27 | 48 | 49 | 50 | 52 |
| Cash flow | ||||||
| Cash from operations | −32 | −52 | −76 | −47 | −22 | −30 |
| Capital expenditure | 1 | 1 | 1 | 1 | 0 | 0 |
| Free cash flow | −33 | −53 | −77 | −48 | −23 | −30 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 5 | 13 | 15 | 17 | 13 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 62 | 261 | 185 | 138 | 120 | 92 |
| Debt incl. finance leases | 32 | 35 | 35 | 35 | 40 | 42 |
| Total assets | 73 | 280 | 213 | 167 | 143 | 115 |
| Total liabilities | 44 | 48 | 53 | 46 | 55 | 51 |
| Shareholders' equity | −89 | 232 | 160 | 120 | 88 | 64 |
| Margins and ratios | ||||||
| Gross margin | 66.7% | 82.4% | 82.7% | 85.3% | 85.5% | 86.2% |
| Operating margin | −116.5% | −105.2% | −117.7% | −70.7% | −63.3% | −48.0% |
| Net margin | −125.5% | −128.6% | −120.9% | −68.5% | −64.5% | −49.7% |
| Free cash flow margin | −119.8% | −109.0% | −107.9% | −59.2% | −28.5% | −38.7% |
| Rule of 40 (growth + FCF margin) | — | −31.9% | −62.1% | −45.5% | −29.9% | −41.8% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −87.9% | −44.0% | −39.6% | −49.6% | −50.7% |
| Return on assets | — | −35.7% | −35.0% | −29.3% | −33.3% | −29.8% |
| Net debt to EBITDA | — | — | — | — | — | — |